Biocon Biologics Gains Health Canada Nod for Yesintek, Expands in North America

Biocon Biologics Ltd has received Health Canada approval for its autoimmune treatment medications Yesintek and Yesintek IV. This approval enhances Biocon's North American presence, providing Canadian patients affordable options for managing chronic autoimmune conditions. With this launch, Biocon extends its global reach on the back of a successful US market entry.

Biocon Ltd announced today that its subsidiary, Biocon Biologics Ltd, has secured Health Canada's approval for the autoimmune treatment drugs Yesintek and Yesintek IV.

The approval from Health Canada includes both Yesintek (ustekinumab injection) and Yesintek IV (ustekinumab for intravenous infusion), as disclosed in a regulatory statement by Biocon Ltd.

This Canadian endorsement marks a pivotal step in Biocon Biologics' mission to broaden accessibility to high-quality biosimilars internationally, bolstering its footprint in North America with a cost-effective treatment for chronic autoimmune disorders.

(With inputs from agencies.)